Biobehavioral, immune, and health benefits following recurrence for psychological intervention participants

Clinical Cancer Research

Volumn 16, Issue 12, 2010, Pages 3270-3278

  Andersen, Barbara L ^a   Thornton, Lisa M ^a   Shapiro, Charles L ^a   Farrar, William B ^a   Mundy, Bethany L ^a   Yang, Hae Chung ^a   Carson III, William E ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CELL PROLIFERATION; CYTOTOXICITY; DISTRESS SYNDROME; FOLLOW UP; HEALTH BEHAVIOR; HUMAN; IMMUNE STATUS; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOLOGICAL AND PSYCHIATRIC PROCEDURES, TECHNIQUES AND CONCEPTS; RECURRENCE RISK; RELAXATION TRAINING; SOCIAL SUPPORT; T LYMPHOCYTE;

BEHAVIOR; BREAST NEOPLASMS; FEMALE; HUMANS; INSURANCE BENEFITS; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PSYCHOTHERAPY; RECURRENCE; SURVIVAL ANALYSIS;

EID: 77953713557     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0278     Document Type: Article

References (50)

1. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychological factors contribute to cancer incidence and survival: a systematic review and meta-analysis. Nat Clin Pract Oncol 2008; 5:466-75.
2. Quinten C, Coens C, Mauer M, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009;10:865-71.
3. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. Am Psychol 1994;49:389-404.
4. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004;22:3570-80.
5. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 2007;21:953-61.
6. Andersen BL, Yang H-C, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer 2008;113:3450-8.
7. Andersen BL, Shapiro CL, Farrar WB, Crespin TR, Wells-Di Gregorio SM. Psychological responses to cancer recurrence: a controlled prospective study. Cancer 2005;104:1540-7.
8. Yang H-C, Brothers BM, Andersen BL. Stress and quality of life in breast cancer recurrence: moderation or mediation of coping? Ann Behav Med 2008;35:188-97.
9. Mahon SM, Cella DF, Donovan MI. Psychosocial adjustment to recurrent cancer. Oncol Nurs Forum 1990;17:47-54.
10. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34. (Pubitemid 29199908)
11. Andersen B, Golden-Kreutz DM, Emery CF, Thiel DL. Biobehavioral intervention for cancer stress: conceptualization, components, and intervention strategies. Cogn Behav Pract 2009;16:253-65.
12. Curran SL, Andrykowski KJ, Studts JL. Short form of the Profile of Mood States (POMS-SF): psychometric information. Psychol Assess 1995;7:80-3.
13. McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, CA: Educational and Industrial Testing Sevices; 1971.
14. Cohen S, Mermelstein R, Kamarck T, Hoberman H. Measuring the functional components of social support. In: Sarason IG, Sarason BR, editors. Social support: theory, research and application. The Hague, Holland: Martinus Nijhoff; 1985, p. 73-94.
15. Procidano ME, Heller K. Measures of perceived social support from friends and from family: three validation studies. Am J Community Psychol 1983;11:1-24.
16. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: Winters R, Ewan H, editors. Important advances in oncology. Philadelphia, PA: J.B. Lippincott Company; 1988, p. 121-41.
17. Carson WE III, Shapiro CL, Crespin TR, Thornton LM, Andersen BL. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004;10:3401-9.
18. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York, NY: Columbia University Press; 1949, p. 199-205.
19. Cox DR. Regression models and life-tables. J R Stat Soc 1972;34: 187-220.
20. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: principles & practice of oncology. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
21. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 2003;89:781-6.
22. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York, NY: Springer-Verlag; 2001.
23. Hosmer DW, Lemeshow S, May S. Applied survival analysis: regression modeling of time to event data. 2nd ed. New York, NY: Wiley; 2008.
24. Raudenbush SW, Bryk AS. Hierarchical linear models. Newbury Park, CA: Sage; 2002.
25. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyze unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-80. (Pubitemid 27458250)
26. Rosenthal R. Parametric measures of effect size. In: Cooper H, Hedges LV, editors. The handbook of research synthesis. New York, NY: Russell Sage; 1994, p. 231-44.
27. Yang H-C, Thornton LM, Shapiro CL, Andersen BL. Surviving recurrence: psychological and quality of life recovery. Cancer 2008; 112:1178-87.
28. Armstrong DK, Davidson NE. Dose intensity for breast cancer. Oncology 2001;15:701-18.
29. Jones D, Ghersi D, Wilcken N. Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 2006;3:CD003368.
30. Carson WE, Liang MI. Current immunotherapeutic strategies in breast cancer. Surg Oncol Clin N Am 2007;16:841-60.
31. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9: 617-32. (Pubitemid 39546403)
32. Andersen BL, Farrar WB, Golden-Kreutz D, et al. Stress and immune responses after surgical treatment for regional breast cancer. J Natl Cancer Inst 1998;90:30-6. (Pubitemid 28078078)
33. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003;105:717-23.
34. Nakamura H, Kawasaki N, Hagiwara M, Saito M, Konaka C, Kato H. Cellular immunologic parameters related to age, gender, and stage in lung cancer patients. Lung Cancer 2000;28:139-45.
35. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998;83: 58-63.
36. Levy S, Tempe JL, Caussade P, et al. Stage-related decrease in natural killer cell activity in untreated patients with mycosis fungoides. Cancer Immunol Immunother 1984;18:138-40.
37. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol 2001;96:574-8.
38. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
39. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008;27:11-18.
40. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008;84:988-93.
41. Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 2006;108:246-52.
42. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27:5904-12.
43. Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 1996;88:2279-87.
44. Goodwin PJ, Leszcz M, Ennis M. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001; 345:1719-26.
45. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: Survival and psychosocial outcome from a randomized controlled trial. Psychooncology 2007;16:277.
46. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportiveexpressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 2007;110: 1130-8.
47. Kissane DW, Bloch S, Smith GC, et al. Cognitive-existential group psychotherapy for women with primary breast cancer: a randomized controlled trial. Psychooncology 2003;12:532-46.
48. Spiegel D, Classen C. Group therapy for cancer patients: a research-based handbook of psychosocial care. New York: Basic/Perseus Books; 2000.
49. Andersen BL. Biobehavioral outcomes following psychological interventions for cancer patients. J Consult Clin Psychol 2002;70: 590-610.
50. Meyer T, Mark M. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol 1995;14:101-8.